2024-11-26 |
[Spotlight] Lifetime non-smoker survives stage IV lung cancer four times |
Tony Kirby |
|
2024-11-26 |
[Comment] 5 years of COVID-19: equity must lead the next pandemic response in a fractured multipolar world |
David S C Hui, Dorothy Yeboah-Manu, Jean B Nachega, Alfonso J Rodriguez-Morales, Tieble Traore, Markus Maeurer, Guiseppe Ippolito, Adam Zumla, Rizwan Ahmed, Osman Dar, Adeeba Kamarulzaman, Alimuddin Zumla |
|
2024-11-23 |
[Articles] Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts |
Joe G Zein, Nazanin Zounemat-Kerman, Ian M Adcock, Bo Hu, Amy Attaway, Mario Castro, Sven-Erik Dahlén, Loren C Denlinger, Serpil C Erzurum, John V Fahy, Benjamin Gaston, Annette T Hastie, Elliot Israel, Nizar N Jarjour, Bruce D Levy, David T Mauger, Wendy |
|
2024-11-23 |
[Comment] A composite burden score for severe asthma |
Jean Bousquet, Renaud Louis, Bernardo Sousa-Pinto |
|
2024-11-23 |
[Corrections] Correction to Lancet Respir Med 2024; published online Oct 29. https://doi.org/10.1016/S2213-2600(24)00264-9 |
|
|
2024-11-22 |
[Articles] Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial |
Dongsheng Yue, Wenxiang Wang, Hongxu Liu, Qixun Chen, Chun Chen, Lunxu Liu, Peng Zhang, Guofang Zhao, Fan Yang, Guang Han, Ying Cheng, Bentong Yu, Yue Yang, Haiquan Chen, Jie Jiang, Lijie Tan, Shidong Xu, Naiquan Mao, Jian Hu, Lanjun Zhang, Bin Yao, Sheng |
|
2024-11-22 |
[Comment] New territories: perioperative chemoimmunotherapy in early-stage NSCLC |
Yusuke Okuma |
|
2024-11-21 |
[Editorial] One health, one flu: the re-emergence of avian influenza |
The Lancet Respiratory Medicine |
|
2024-11-16 |
[News] Health care in Ukraine: If everybody leaves, who will stay? |
Talha Burki |
|
2024-11-14 |
[Articles] Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis |
Amy Shackleford, Liam G Heaney, Charlene Redmond, P Jane McDowell, John Busby |
|
2024-11-14 |
[Comment] Asthma remission: a call for a globally standardised definition |
Marek Lommatzsch, J Christian Virchow |
|
2024-11-14 |
[Spotlight] Thoracentesis: an old story and some new sources |
Emmanuel Drouin, Eric Wiel, Edouard Lansiaux, Jacalyn Duffin, Arnaud Chambellan |
|
2024-11-12 |
[Comment] Managing tuberculosis before the onset of symptoms |
Dennis Falzon, Cecily Miller, Irwin Law, Katherine Floyd, Nimalan Arinaminpathy, Matteo Zignol, Tereza Kasaeva |
|
2024-10-31 |
[Correspondence] Health promotion in the management of respiratory diseases: an Indian perspective |
Arundhati Garud, Debabani Biswas, Saibal Moitra, Subhabrata Moitra |
|
2024-10-30 |
[Articles] Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, pha |
Hervé Léna, Laurent Greillier, Claire Cropet, Olivier Bylicki, Isabelle Monnet, Clarisse Audigier-Valette, Lionel Falchero, Alain Vergnenègre, Pierre Demontrond, Margaux Geier, Florian Guisier, Stéphane Hominal, Chrystèle Locher, Romain Corre, Christos Ch |
|
2024-10-30 |
[Comment] First-line treatment for advanced NSCLC in older patients and those with poor performance status |
Ziming Li, Shun Lu |
|
2024-10-26 |
[Articles] Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study |
Sergio Harari, Davide Elia, Antonella Caminati, Jens Geginat, Francesca Luisi, Giuseppe Pelosi, Claudia Specchia, Olga Torre, Roberta Trevisan, Chiara Vasco, Maurizio Zompatori, Roberto Cassandro |
|
2024-10-26 |
[Comment] The challenge of therapeutic options for patients with lymphangioleiomyomatosis |
Maria Molina-Molina |
|
2024-10-24 |
[News] Youth vaping rates drop in US, but experts remain concerned |
Bryant Furlow |
|
2024-10-23 |
[News] UK COVID-19 booster vaccination programme |
Priya Venkatesan |
|
2024-10-19 |
[Articles] Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 |
GBD 2021 Pulmonary Arterial Hypertension Collaborators |
|
2024-10-19 |
[Comment] The global burden of pulmonary arterial hypertension: profound but improving? |
Joseph Newman, Joanna Pepke-Zaba |
|
2024-10-19 |
[Corrections] Correction to Lancet Respir Med 2024; 12: 799–809 |
|
|
2024-10-18 |
[News] Mixed news on air pollution and child lung health |
Udani Samarasekera |
|
2024-10-16 |
[Comment] Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis |
Marjolein Drent, Anne-Marie Russell, Lesley Ann Saketkoo, Paolo Spagnolo, Marcel Veltkamp, Athol U Wells, representatives of the sarcoidosis community |
|
2024-10-12 |
[Viewpoint] Empirical antibiotic therapy for sepsis: save the anaerobic microbiota |
Robert F J Kullberg, Bastiaan W Haak, Rishi Chanderraj, Hallie C Prescott, Robert P Dickson, W Joost Wiersinga |
|
2024-10-12 |
[Editorial] Antimicrobial resistance: a global health emergency |
The Lancet Respiratory Medicine |
|
2024-10-11 |
[Spotlight] Survival of sepsis masked by medications that hid diverticulitis |
Tony Kirby |
|
2024-10-10 |
[Correspondence] Airway inflammation enhances the effectiveness of elexacaftor–tezacaftor–ivacaftor therapy for cystic fibrosis and CFTRN1303K mutation |
Martina Gentzsch, Charles R Esther, Carla M P Ribeiro |
|
2024-10-09 |
[News] Phillip Morris sell Vectura after academic freeze-out |
Talha Burki |
|
2024-10-04 |
[News] European Respiratory Society International Congress 2024 |
Priya Venkatesan |
|
2024-10-02 |
[Articles] Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial |
Ruth L Goodall, Andrew J Nunn, Sarah K Meredith, Adamu Bayissa, Anuj K Bhatnagar, Chen-Yuan Chiang, Francesca Conradie, Narendran Gopalan, Meera Gurumurthy, Bruce Kirenga, Nana Kiria, Daniel Meressa, Ronelle Moodliar, Nosipho Ngubane, Mohammed Rassool, Ka |
|
2024-10-02 |
[Comment] Towards shorter, safer, flexible, and more effective treatment regimens for drug-resistant tuberculosis |
Keertan Dheda, Christoph Lange |
|
2024-09-27 |
[Comment] Strengthening intensive care: addressing challenges and embracing opportunities |
Elie Azoulay, Maurizio Cecconi, Jan J De Waele |
|
2024-09-24 |
[Comment] Reflections 5 years on from the approval of ETI therapy |
Peter G Middleton, Jennifer L Taylor-Cousar |
|
2024-09-20 |
[Comment] Serotonin pathway blockade in pulmonary arterial hypertension |
Marcin Kurzyna |
|
2024-09-20 |
[Articles] Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial |
Olivier Sitbon, Andris Skride, Jeremy Feldman, Sandeep Sahay, Oksana A Shlobin, Vallerie McLaughlin, Hossein-Ardeschir Ghofrani, David Langleben, Ed Parsley, Gwyn D'Souza, Tonya Marmon, Watiri Kamau-Kelley, Renee Jones, Ravi Grewal, Steve Wring, Michelle |
|
2024-09-19 |
[Articles] Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial |
Ze-Rui Zhao, Shi-Liang Liu, Ting Zhou, Gang Chen, Hao Long, Xiao-Dong Su, Xu Zhang, Jian-Hua Fu, Peng Lin, Lan-Jun Zhang, Tie-Hua Rong, Jia-Di Wu, Zhi-Chao Li, Hui-Lin Su, Ji-Yang Chen, Yun-Peng Yang, Yong-Bin Lin, Mian Xi, Hong Yang |
|
2024-09-19 |
[Comment] Stereotactic body radiotherapy plus neoadjuvant chemoimmunotherapy in operable non-small-cell lung cancer |
Rafał Dziadziuszko, Bartłomiej Tomasik |
|
2024-09-17 |
[Editorial] Extreme heat: holistic thinking in respiratory medicine |
The Lancet Respiratory Medicine |
|
2024-09-13 |
[Correspondence] Top ten research priorities for sepsis research: UK James Lind Alliance priority setting partnership |
Joanne McPeake, Mark Oakes, Colin Graham, Nahid Ahmad, Nazir Lone, Bronwen Connolly, James Lind Alliance Sepsis PSP Steering Group |
|
2024-09-11 |
[Articles] Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory st |
Yongfeng Yu, Qisen Guo, Yongchang Zhang, Jian Fang, Diansheng Zhong, Baogang Liu, Pinhua Pan, Dongqing Lv, Lin Wu, Yanqiu Zhao, Juan Li, Zhihua Liu, Chunling Liu, Haichuan Su, Yun Fan, Tongmei Zhang, Anwen Liu, Bo Jin, Ye Wang, Jianying Zhou, Zhihong Zhan |
|
2024-09-11 |
[Comment] Savolitinib in NSCLC: progress in the MET exon 14 journey |
Tetsuya Mitsudomi |
|
2024-09-10 |
[Articles] Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months |
Charles S Haworth, Michal Shteinberg, Kevin Winthrop, Alan Barker, Francesco Blasi, Katerina Dimakou, Lucy C Morgan, Anne E O'Donnell, Felix C Ringshausen, Oriol Sibila, Rachel M Thomson, Kevin J Carroll, Federica Pontenani, Paola Castellani, James D Chal |
|
2024-09-10 |
[Comment] PROMISing results for inhaled antibiotics in bronchiectasis |
Marta María García Clemente, Guillermo Suárez Cuartín |
|
2024-09-10 |
[Articles] Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled tr |
Baohui Han, Trevor Feinstein, Yuankai Shi, Gongyan Chen, Yu Yao, Chunhong Hu, Jianhua Shi, Jifeng Feng, Huijuan Wu, Ying Cheng, Qi-sen Guo, Zhijun Jie, Feng Ye, Yiping Zhang, Zhihua Liu, Weidong Mao, Liangming Zhang, Junguo Lu, Jun Zhao, Lyudmila Bazhenov |
|
2024-09-10 |
[Comment] Plinabulin, a microtubule destabilising agent, in non-small-cell lung cancer: lessons from the DUBLIN-3 trial |
Rafael Rosell, María González-Cao, Miguel Angel Molina-Vila |
|
2024-09-09 |
[Articles] Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial |
Irene J Higginson, Sarah T Brown, Adejoke O Oluyase, Peter May, Matthew Maddocks, Massimo Costantini, Sabrina Bajwah, Charles Normand, Claudia Bausewein, Steffen T Simon, Karen Ryan, David C Currow, Miriam J Johnson, Simon P Hart, Hannah Mather, Malgorzat |
|
2024-09-09 |
[Comment] The ongoing battle against breathlessness |
Kris Mooren, Huib A M Kerstjens |
|
2024-09-09 |
[Comment] Choice overload for RSV prevention—how to form your opinion |
Natasha Halasa, Louis Bont |
|
2024-09-09 |
[Spotlight] Louis Bont – leading efforts to find an RSV vaccine |
Tony Kirby |
|
2024-09-09 |
[Series] Early-life respiratory syncytial virus disease and long-term respiratory health |
Heather J Zar, Ferdinand Cacho, Tahira Kootbodien, Asuncion Mejias, Justin R Ortiz, Renato T Stein, Tina V Hartert |
|
2024-09-09 |
[Series] Respiratory syncytial virus infections in adults: a narrative review |
Joanne G Wildenbeest, David M Lowe, Joseph F Standing, Christopher C Butler |
|
2024-09-05 |
[Comment] ECMO: more than just a bridge over troubled waters? |
Ryan Ruiyang Ling, Kollengode Ramanathan, Kiran Shekar |
|
2024-09-05 |
[Comment] Continuing ECMO with no possible transition to recovery or transplant |
Alexander Supady, William L Allen, Thaddeus M Pope |
|
2024-08-31 |
[Articles] Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial |
Surinder S Birring, Linda Cardozo, Roger Dmochowski, Peter Dicpinigaitis, Amna Afzal, Carmen La Rosa, Susan Lu, Allison Martin Nguyen, Ruji Yao, Paul A Reyfman |
|
2024-08-31 |
[Comment] Easing the stress of chronic cough |
Marta Dąbrowska, Lorcan McGarvey |
|
2024-08-29 |
[Position Paper] An international consensus on the use of asthma biologics in pregnancy |
Jennifer Naftel, David J Jackson, Matthew Coleman, Grainne d'Ancona, Liam G Heaney, Paddy Dennison, Apostolos Bossios, Hitasha Rupani |
|
2024-08-29 |
[Comment] Navigating uncertainty: asthma biologics during pregnancy |
Imran Howell, Aleksandra Howell, Ian Pavord |
|
2024-08-27 |
[Comment] Expanding the indication of CFTR modulator combinations for people with cystic fibrosis with non-F508del variants |
Pierre-Régis Burgel |
|
2024-08-27 |
[Articles] Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial |
George M Solomon, Rachel W Linnemann, Rachel Rich, Ashleigh Streby, Brian Buehler, Eric Hunter, Kadambari Vijaykumar, William R Hunt, John J Brewington, Andras Rab, Shasha P Bai, Adrianna L Westbrook, Carmel McNicholas-Bevensee, Jong Hong, Candela Manfred |
|
2024-08-22 |
[News] The UK COVID-19 Inquiry and critical care |
Priya Venkatesan |
|
2024-08-22 |
[Spotlight] One lung but many laughs at the Edinburgh Festival Fringe |
Peter Ranscombe |
|
2024-08-22 |
[Spotlight] Saving lives with oxygen and monocytes at Edinburgh Fringe |
Peter Ranscombe |
|
2024-08-21 |
[Comment] New thinking and a new direction in bronchiectasis |
Ian D Pavord |
|
2024-08-17 |
[Articles] Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, rando |
Yoshimasa Shiraishi, Shogo Nomura, Shunichi Sugawara, Hidehito Horinouchi, Yasuto Yoneshima, Hidetoshi Hayashi, Koichi Azuma, Satoshi Hara, Seiji Niho, Ryo Morita, Masafumi Yamaguchi, Toshihide Yokoyama, Kiyotaka Yoh, Takayasu Kurata, Hiroaki Okamoto, Mas |
|
2024-08-17 |
[Spotlight] Fatal dyspnoea at the Palace of Versailles |
Emmanuel Drouin, Serge Wasersztrum, Arnaud Chambellan |
|
2024-08-17 |
[Comment] Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON study |
Molly S C Li, Stephanie P L Saw, Alfredo Addeo |
|
2024-08-15 |
[Editorial] FLiRTing with danger as SARS-CoV-2 variants evolve |
The Lancet Respiratory Medicine |
|
2024-08-14 |
[Comment] Compassionate use trials and equitable access to variant-specific treatment for cystic fibrosis |
Katherine Odem-Davis, Jennifer L Taylor-Cousar |
|
2024-08-14 |
[Articles] The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study |
Pierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, Isabelle Durieu, Véronique Houdouin, Camille Audousset, Julie Macey, Dominique Grenet, Michele Porzio, Marlène Murris-Espin, Philippe Reix, Mélisande Baravalle, Chantal Belleguic, Laurent |
|
2024-08-13 |
[Articles] High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial |
Jiayi Yu, Leilei Jiang, Lina Zhao, Xue Yang, Xiaomin Wang, Dan Yang, Minglei Zhuo, Hanxiao Chen, Wei Huang, Zhengfei Zhu, Min Zhang, Yipeng Song, Quanfu Li, Zhanshu Ma, Qifeng Wang, Yanli Qu, Rong Yu, Huiming Yu, Jun Zhao, Anhui Shi, Trial Management Grou |
|
2024-08-13 |
[Comment] New strategies for patients with limited-stage small-cell lung cancer |
Famke L Schneiders, Suresh Senan |
|
2024-08-09 |
[Comment] Patient-reported outcomes: missing in asthma remission |
Amy Hai Yan Chan, Paul Leong, John Politis, Vanessa M McDonald, Philip Bardin |
|
2024-08-08 |
[Articles] Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study |
Margaux M I Meslé, Jeremy Brown, Piers Mook, Mark A Katz, José Hagan, Roberta Pastore, Bernhard Benka, Monika Redlberger-Fritz, Nathalie Bossuyt, Veerle Stouten, Catharina Vernemmen, Elisabet Constantinou, Marek Maly, Jan Kynčl, Ondrej Sanca, Tyra Grove K |
|
2024-08-08 |
[Comment] Impact of COVID-19 vaccination programmes in Europe: lives saved and lessons learned |
Oliver J Watson, Alexandra B Hogan |
|
2024-08-02 |
[News] US FDA approves menthol e-cigarette products |
Bryant Furlow |
|
2024-07-24 |
[Comment] Foritinib, a type II ROS1 inhibitor for NSCLC |
Jii Bum Lee, Sai-Hong Ignatius Ou |
|
2024-07-24 |
[Articles] Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study |
Jin-Ji Yang, Jianying Zhou, Si-Yang Maggie Liu, Mingjun Li, Zhiye Zhang, Ying Cheng, Yun Fan, Hongming Pan, Baoqing Wang, Gongyan Chen, Ke Wang, Liyan Jiang, Yanping Hu, Jianhua Shi, Xiaorong Dong, Cuimin Ding, Yunpeng Liu, Zhe Liu, Wangjun Liao, Wei Li, |
|
2024-07-20 |
[Correspondence] Sedation targets in the ICU: thinking beyond protocols |
Bruna Brandao Barreto, Mariana Luz, Dimitri Gusmao-Flores |
|
2024-07-17 |
[News] US Supreme Court overturns Chevron doctrine |
Bryant Furlow |
|
2024-07-16 |
[Articles] Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation |
Hernan P Fainberg, Yuben Moodley, Isaac Triguero, Tamera J Corte, Jannie M B Sand, Diana J Leeming, Morten A Karsdal, Athol U Wells, Elisabetta Renzoni, John Mackintosh, Dino B A Tan, Roger Li, Joanne Porte, Rebecca Braybrooke, Gauri Saini, Simon R Johnso |
|
2024-07-16 |
[Review] Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients |
Simon Feys, Agostinho Carvalho, Cornelius J Clancy, Jean-Pierre Gangneux, Martin Hoenigl, Katrien Lagrou, Bart J A Rijnders, Laura Seldeslachts, Lore Vanderbeke, Frank L van de Veerdonk, Paul E Verweij, Joost Wauters |
|
2024-07-16 |
[Comment] Biomarker-defined endotypes of pulmonary fibrosis |
A Scott McCall, Jonathan A Kropski |
|
2024-07-13 |
[Spotlight] Alin Gragossian: from emergency medicine resident to heart transplant recipient |
Tony Kirby |
|
2024-07-12 |
[Articles] Nasal sprays and behavioural interventions compared with usual care for acute respiratory illness in primary care: a randomised, controlled, open-label, parallel-group trial |
Paul Little, Jane Vennik, Kate Rumsby, Beth Stuart, Taeko Becque, Michael Moore, Nick Francis, Alastair D Hay, Theo Verheij, Katherine Bradbury, Kate Greenwell, Laura Dennison, Sian Holt, James Denison-Day, Ben Ainsworth, James Raftery, Tammy Thomas, Chri |
|
2024-07-12 |
[Comment] Treating acute respiratory illness: the need to be proactive |
Evangelos J Giamarellos-Bourboulis |
|
2024-07-10 |
[Spotlight] Fasting in Ramadan and respiratory diseases |
Talha Burki |
|
2024-07-09 |
[Health-care Development] Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review |
Sjanna B Besteman, Debby Bogaert, Louis Bont, Asuncion Mejias, Octavio Ramilo, Daniel M Weinberger, Ron Dagan |
|
2024-07-09 |
[Spotlight] James Chalmers: A maverick making an impact in bronchiectasis |
Peter Ranscombe |
|
2024-07-04 |
[Review] Rethinking bronchiectasis as an inflammatory disease |
Merete B Long, Sanjay H Chotirmall, Michal Shteinberg, James D Chalmers |
|
2024-06-21 |
[News] Whooping cough cases rising |
Priya Venkatesan |
|
2024-06-15 |
[Review] Biological and therapeutic implications of the cancer-related germline mutation landscape in lung cancer |
Emmanouil Panagiotou, Ioannis A Vathiotis, Periklis Makrythanasis, Fred Hirsch, Triparna Sen, Konstantinos Syrigos |
|
2024-06-15 |
[Correspondence] Potential for personalised and biomarker-guided COPD self-treatment approaches |
Anke Lenferink, Emanuel Citgez, Paul D L P M van der Valk, Job van der Palen, Tanja W Effing, Marjolein G J Brusse-Keizer |
|
2024-06-14 |
[Comment] Moving forward in IPF: lessons learned from clinical trials |
Ganesh Raghu, Thomas R Fleming |
|
2024-06-13 |
[Correspondence] Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials |
Brady Thomas, Patrick McNamara, Jennifer Bermick |
|
2024-06-13 |
[Correspondence] Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials – Authors' reply |
John Lowe, Janet Berrington, David Gillespie, Mark Turner, Sailesh Kotecha |
|
2024-06-12 |
[Articles] Hypothermia for expanded criteria organ donors in kidney transplantation in France (HYPOREME): a multicentre, randomised controlled trial |
The HYPOREME Trial Group |
|
2024-06-12 |
[Comment] Mild hypothermia for expanded criteria kidney donors: balancing evidence and uncertainty |
Riccardo Campi, Vincenzo Li Marzi, Sergio Serni |
|
2024-06-12 |
[News] 2024 American Thoracic Society International Conference |
Priya Venkatesan |
|